Lightnews — Scholar-powered news

Reposted by Marina Khan

UK Oncology Nursing Society @ukons.bsky.social · 11d

Calling all Young and Early Career Cancer Nurses (YECCN)

The YECCN MIG is currently looking for 1x MIG Chair, 1x secretary and 8x committee members.

If interested & under 35/working for <5yrs, please email by 5th October, a 300 word expression of interest to:

[email protected]

#YECCN

1 1

Reposted by Marina Khan

American Society of Clinical Oncology @ascocancer.bsky.social · 19d

Exciting news! We’ve launched ASCO Edge, an online oncology practice management educational series exclusively available to ASCO members.

Get started today: brnw.ch/21wVVu3

2 2

Reposted by Marina Khan

Joanne Clements 🕷💙🦋 @joannekarma.bsky.social · 19d

Please check out this from We Own It.

weownit.org.uk/act-now/new-...

Say no to new PFI in our NHS - take action

The government’s new 10-Year Plan for Health is proposing to bring disastrous private finance deals back into our NHS.

weownit.org.uk

4 4

Reposted by Marina Khan

OncoDaily @oncodaily.bsky.social · 27d

Drew Moghanaki and Gerry Hanna Discuss Survival and Toxicity of New Phase 3 Trial in LS-SCLC

@drewmoghanaki.bsky.social @gerryhanna.bsky.social

oncodaily.com/voices/drew-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SCLC #LungCancer

Drew Moghanaki and Gerry Hanna Discuss Survival and Toxicity of New Phase 3 Trial in LS-SCLC - OncoDaily

Drew Moghanaki and Gerry Hanna Discuss Survival and Toxicity of New Phase 3 Trial in LS-SCLC / cancer, Drew Moghanaki, Gerry Hanna, LS-SCLC, OncoDaily, Oncology

oncodaily.com

2 4

Reposted by Marina Khan

European Society for Radiotherapy and Oncology (ESTRO) @estroradiotherapy.bsky.social · 26d

Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the #radiotherapy delineation benchmark case procedure, published in the Green Journal.
👉 Read it before your patients: bit.ly/4fLoatJ

2 3

Reposted by Marina Khan

Clive Peedell @drpeedell.bsky.social · 27d

New #radiotherapy innovations are being stifled by the tortuous commissioning process. Patients deserve better! #radonc #oncology #medtwitter
Postcode lottery for new cancer treatments, doctors warn - BBC News www.bbc.co.uk/news/article...

Postcode lottery for new cancer treatments, doctors warn

Experts say bureaucracy is

www.bbc.co.uk

1 1 6

Reposted by Marina Khan

EORTC Quality of Life Group (QLG) @qol.eortc.org · 27d

📢 Attending #EAPM2025 this week?
Today, our @eortc.org #QualityofLife Group member Ines Rathgeber will report on the development of an e-learning course focusing on the use of EORTC PRO measures for quality of life assessment in clinical practice 👇

eapm.eu.com/2025-eapm-co...

#CancerResearch

1 1

Reposted by Marina Khan

Let's Win Pancreatic Cancer @letswinpc.org · Sep 4

✅ Finished treatment or on maintenance for #PancreaticCancer? We’ve got resources to help.

Find tips on managing side effects, eating well, coping with scanxiety, and staying up to date on the latest research. https://bit.ly/4lX0owd #GuideToAction #LetsWinPC

Living With

You may be undergoing maintenance treatment or you may have completed treatment but you are still part of the pancreatic cancer community.

bit.ly

1 1

Reposted by Marina Khan

OncoDaily @oncodaily.bsky.social · Aug 10

One Voice for Radiotherapy: Creating World Radiotherapy Awareness Day

oncodaily.com/insight/one-...

#Cancer #Oncology #OncoDaily #Health #Medicine

One Voice for Radiotherapy: Creating World Radiotherapy Awareness Day - OncoDaily

One Voice for Radiotherapy: Creating World Radiotherapy Awareness Day / cancer, Katie Wakeham, OncoDaily, Oncology, One Voice For Radiotherapy, radiation

oncodaily.com

3 9

Reposted by Marina Khan

Dr Laura Charlesworth [PhD] @lcharlesworth.bsky.social · Aug 1

Putting Patients First: Transforming Cancer Diagnosis, Treatment and Care Through Patient-Centred Approaches.

In this guest editorial, we reflect on why meaningful progress & the delivery of high quality cancer care requires more than technical innovation

www.radiographyonline.com/article/S107...

Putting patients first: Transforming cancer diagnosis, treatment and care through patient-centred approaches

Delivering high quality care is at the forefront of the cancer agenda for professionals and policy makers alike. Whilst it is clear that drug development alongside technical innovations and advancemen...

www.radiographyonline.com

1 2

Reposted by Marina Khan

BTOG @btog.bsky.social · Aug 1

Today on #WorldLungCancerDay, we reaffirm our mission to support thoracic oncology professionals and advocate for equitable, world-class care for all patients.

Together, we strive to match the best survival rates globally. 💙
#WLCD2025 #LungCancerAwareness #LCSM #lungcancer

1 2

Reposted by Marina Khan

Giorgio Seano @giorgioseano.bsky.social · Jul 17

🧠 Why does glioblastoma always outsmart treatment? In our #Neuro-Oncology paper, we identified proneural-mesenchymal hybrid glioblastoma cells that are resistant to therapy and dependent on nuclear import. doi.org/10.1093/neuo...
Short walkthrough below. Let’s dive in! 🧵 (1/9)
#GBM, #BrainTumor

Background: Despite extensive research efforts, glioblastoma (GBM) remains a deadly disease with poor prognosis. Although previous studies have identified various cell states within GBM tumors, the molecular mechanism underlying adaptive GBM cell plasticity induced by conventional therapy remains unclear.
Methods: We used fluorescent reporters for proneural (PN) and mesenchymal (MES) subtypes to monitor GBM cell plasticity in real-time across multiple patient-derived cell lines. This approach revealed cells that concurrently expressed both proneural and mesenchymal markers. To investigate this unique hybrid population, we implemented a comprehensive methodological approach encompassing bulk and single-cell RNA sequencing, single-cell ChIP sequencing, nuclear proteomics, high-resolution imaging, orthotopic mouse models, clinical dataset analysis, and pharmacological and genetic techniques. This multifaceted strategy allowed us to gain functional and molecular insights into this distinct cellular population.
Results: We showed that these hybrid cells are increased by conventional therapies, and are resistant to these therapies. At the molecular level, hybrid cells display significant alterations in chromatin structure and nuclear protein composition, elevated transcriptional activity, Myc activation, and improved transport between the nucleus and cytoplasm. Genetic and pharmaceutical inhibition of the nuclear import/export shuttling machinery, increased in hybrid cells, effectively suppressed adaptive GBM cell plasticity and hybrid identity, thereby enhancing the sensitivity of GBM cells to therapies.
Conclusion: Our results indicate that GBM hybrid cells play a crucial role in chemoradiation resistance. The nuclear transport machinery presents a potential therapeutic target for hybrid cells, offering a way to counteract the typical resistance to treatment observed in GBM.

2 6 9

Reposted by Marina Khan

Dr Liz O’Riordan @lizoriordan.bsky.social · Jul 19

BREAKING NEWS

Scientists at the @icr-ctsu.bsky.social have discovered how to predict which ER+ HER2+ cancers have a higher risk of recurrence in just 2 weeks!

Breaking news - Breast Cancer Breakthrough! #breastcancer
youtube.com/shorts/3rYUU...

Breaking news - Breast Cancer Breakthrough! #breastcancer

YouTube video by Dr Liz O'Riordan

youtube.com

2 12 43

Reposted by Marina Khan

Stephen Tozer-Loft @to-lo.co.uk · Jul 19

important listen for all involved in #radiotherapy.

pca.st/episode/a767...

"Captain Kirk Forgot to put the Machine on Stun"

pca.st

1 2 4

Reposted by Marina Khan

European Society for Radiotherapy and Oncology (ESTRO) @estroradiotherapy.bsky.social · Jul 17

✨Today is #BrachytherapyAwarenessDay, let's spotlight precision in cancer care.
🎯#Brachytherapy boosts survival, helps preserve function & QoL, yet remains underused.
📢 Oncology professionals:
✅ Raise awareness
✅ Support access
✅ Empower patients
👉https://bit.ly/4lwRdTL

1 2

Reposted by Marina Khan

European Society for Radiotherapy and Oncology (ESTRO) @estroradiotherapy.bsky.social · Jul 3

At #ESTRO25, a heated debate unfolded: “CBCT-based fast adaptation workflows will supersede MR-Linac usage.”
💬 With strong arguments on both sides, the audience shifted from 72% in favour to a near 50/50 split by the end.
👉 bit.ly/3Iavy59

1 1

Reposted by Marina Khan

European Society for Radiotherapy and Oncology (ESTRO) @estroradiotherapy.bsky.social · Jun 26

Congratulations to our journal TipsRO - Technical Innovations and Patient Support in Radiation Oncology for achieving its first Impact Factor of 2.8! A reflection of the quality and dedication of the editorial team, authors, and the entire #RTT community.

2 1

Reposted by Marina Khan

Patty Diez @pattydiezh.bsky.social · Jun 24

A really educational day. Big shoutout to Tom Rackley & Rebecca Muirhead for leading the event & superstars @alison-tree.bsky.social and Dione Lother for sharing their wisdom. Amazing practical insights from @aileenduffton.bsky.social @marina-khan.bsky.social Helen Grimes & Joe Flaherty. Congrats!

Marina Khan @marina-khan.bsky.social · Jun 24

We had the SABR bone and nodes workshop today. @uksabr.bsky.social in collaboration with the RCR. Lots of discussion & learning for all within the SABR MDT. Collaboration at its best. Thank you to all those that attended and especially the speakers. @alison-tree.bsky.social @pattydiezh.bsky.social

1 6

Marina Khan @marina-khan.bsky.social · Jun 24

We had the SABR bone and nodes workshop today. @uksabr.bsky.social in collaboration with the RCR. Lots of discussion & learning for all within the SABR MDT. Collaboration at its best. Thank you to all those that attended and especially the speakers. @alison-tree.bsky.social @pattydiezh.bsky.social

1 3

Reposted by Marina Khan

Deep Chakrabarti @deeponco.bsky.social · Jun 13

Happy to share our review on hypo- and ultra-hypofractionation for prostate cancer radiotherapy, just published in Seminars in Radiation Oncology

@alison-tree.bsky.social @harshanigreen.bsky.social

Full-text link:
authors.elsevier.com/a/1lFrI3lXQo...

3 8

Reposted by Marina Khan

The BMJ @bmj.com · Jun 9

"We’re very clear that research inclusion is essential—not political. If your research isn’t representative, it’s not going to improve outcomes across our population."

Lucy Chappell, chief executive @nihr.bsky.social, explains why research inclusion is vital
www.bmj.com/content/389/...

13 30

Reposted by Marina Khan

ICR-CTSU @icr-ctsu.bsky.social · Jun 9

Are you an experienced #Biostatistician looking for the next step in your #ClinicalTrials career?

We are recruiting for a research group leader to develop and grow our academic clinical trials portfolio. Find out more and apply here:
#StatsJobs #ResearchJobs 🧪
jobs.icr.ac.uk/vacancies/12...

Research Group Leader, ICR Clinical Trials and Statistics Unit (ICR-CTSU) in Sutton | The Institute of Cancer Research

View details and apply for this Research Group Leader, ICR Clinical Trials and Statistics Unit (ICR-CTSU) vacancy in Sutton. Salary: Appointments will be made at the appropriat...

jobs.icr.ac.uk

3 5

Marina Khan @marina-khan.bsky.social · Jun 7

🧠📸 Proud to represent RTTs as part of the 2022 ESTRO Physics Workshop IGRT Working Group! Our expert consensus on optimising CBCT doses for IGRT is now available.

🔗 doi.org/10.1016/j.ra...

#MedPhysics #Radiotherapy #IGRT #ESTRO2022 #MedicalImaging #RadiationOncology #RTT

1 3

Marina Khan @marina-khan.bsky.social · Jun 4

Come and join us in Newcastle in November for all things #SABR at this years @uksabr.bsky.social
#RTT #MedPhys #ClinOnc #Radiotherapy

Patty Diez @pattydiezh.bsky.social · Jun 4

@uksabr.bsky.social is coming to Newcastle!
Save the dates: Annual Professional Conference and pre-conference lung workshop. Wed 19, Thurs 20 & Fri 21 Nov. More details bit.ly/3Zh2YVj - there is no other event like it. @gerryhanna.bsky.social @drpeedell.bsky.social @marina-khan.bsky.social

2

Reposted by Marina Khan

The Institute of Cancer Research @icr.ac.uk · May 30

📰 BREAKING: Researchers show that pembrolizumab, an immunotherapy drug, helps head and neck cancer patients live years longer cancer-free. The drug also hunts down cancer trying to spread.

Results from the the phase III KEYNOTE-689 trial are presented at #ASCO25 ⤵️

www.icr.ac.uk/about-us/icr...

Professor Kevin Harrington from the ICR and The Royal Marsden, who was involved in the study, said: "This research shows that immunotherapy could change the world for these patients -- it significantly increases the chance of remaining free of disease."

1 1 8